Angioedema in renal transplant recipients on sirolimus.
Most drug-associated angioedemas are induced by angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, or nonsteroidal anti-inflammatory drugs. Recently, the responsibility of immunosuppressive agents given to transplant recipients in the development of angioedema has been discussed. To describe, in detail, angioedema episodes in renal transplant recipients (RTRs) on sirolimus. A cross-sectional study in a university hospital. Eighty consecutive RTRs on sirolimus were studied. Angioedema without urticaria occurred a mean of 5 times in 12/80 (15%) RTRs taking sirolimus. It was predominantly located on the face (83%), with mucous membrane involvement in 7 (58%) patients, and was life threatening in 1. Another putative cofactor for angioedema without urticaria was identified in 9 (75%) patients: drugs (n=8), food allergy or physical activity (n=3). Tacrolimus intake was significantly associated with sirolimus-associated angioedema. Our results suggested a causal relationship between sirolimus and angioedema in RTRs.